Elsevier, Inc. Release: Biopharma Leaders Discuss Pharma’s Future at Pharmaceutical Strategic Alliances in New York

BRIDGEWATER, New Jersey, August 8, 2011 /PRNewswire/ --

Elsevier Business Intelligence, the biopharma industry’s leading provider of strategic business intelligence and conferences, is hosting Windhover’s 21stPharmaceutical Strategic Alliances (PSA) September 21-23, 2011 at the Millennium Broadway in New York, NY.

PSA is the only conference of its kind to provide direct access to such a diverse mix of pharma’s top talent. It’s an opportunity to hear first-hand from some of the industry’s most influential minds and leading experts. Chief Executive Officers Lamberto Andreotti of Bristol-Myers Squibb and George Scangos of Biogen Idec are just two of the speakers providing perspectives - and solutions - to the top challenges facing biopharma companies big and small.

Other leading experts from firms such as Pfizer, Johnson and Johnson, Roche and Merck will present information on other important topics facing the biopharma industry, including:

  • R&D Evolution: How Big Pharma Can Get It Right;
  • Lessons Learned from the Changing Oncology Landscape: Industry Perspectives;
  • Biosimilars: What You Need To Know Now;
  • Reimagining Business Development, and many more.

In addition to moderating strategic panels spanning R&D through commercialization, IN VIVO’s editorial team will also present an overview of current deal making trends, providing insights into top trends like academic alliances, creative deal structures, and the importance of innovation in today’s payor-dominated world.

“Pharmaceutical Strategic Alliances is a rare opportunity to provide a discussion of the various, most promising solutions to the industry’s toughest challenges. Call it a tool box for growth - and for those most in need, pharma’s survival kit,” said Elsevier Business Intelligence’s Chris Morrison, Editor-in-Chief, Biopharma and Consumer Products.

To learn more about panel topics and keynote talks, visit: http://www.windhover.com/windhover/content/conferences/psaschedule11.asp

About Windhover Conferences and Elsevier Business Intelligence

Windhover Conferences is an Elsevier Business Intelligence company, the leading provider of business intelligence and analysis to senior executives in the medical device, pharmaceutical, and biotechnology industries. Publishers of The Pink Sheet, IN VIVO: The Business & Medicine Report, PharmAsia News, The Tan Sheet”,Start-Up: Emerging Medical Ventures, and The RPM Report: Regulation Policy Market Access, Elsevier Business Intelligence and Windhover also host a variety of industry meetings and webinars in both medical device and pharma/biotech, and produce a wide array of market research reports. For more on the companies’ products and services, please visit http://www.ElsevierBI.com.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Dianna Flanick
Vice President, Sales & Marketing
Elsevier Business Intelligence
+1-908-547-2141
d.flanick@elsevier.com

SOURCE Elsevier

MORE ON THIS TOPIC